Can The Beachbody Company (BODI) Stock Reach $16?

Key Takeaways

• The central $16 stock price target is the arithmetic mean of four verified analyst price targets, which average $16.25 before rounding.
• The targets span a wide range from $9 (Roth MKM) to $22 (Noble Financial), reflecting genuine disagreement about the turnaround's durability.
• At a recent close of $4.51, BODI would need to gain roughly 255% to reach $16, a very large move.
• Supporting factors include a shift from multi-level marketing to an omni-channel model, sustained positive EBITDA (earnings before interest, taxes, depreciation, and amortization), and retail expansion tied to the GLP-1 wellness trend.
• Key risks are multi-year revenue declines, a micro-cap valuation of about $33 million, thin trading, and analyst targets that were recently cut.
• Because the stock traded near $16 within the past year, the target is not unprecedented, but it still implies a full multi-year recovery from current levels.
• You can explore this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for deeper detail.
• For automated, AI-driven market scanning, explore Trending AI Robots to complement your own research.

Analyst Price Targets and Consensus View

BODI is the stock of The Beachbody Company, Inc., a Nasdaq-listed fitness and nutrition company. Four current, individually attributable analyst price targets form the basis of the $16 central target. Canaccord Genuity analyst Susan Anderson lowered her target to $16 from $19 in late October 2026 while keeping a Buy rating. Noble Financial maintains a $22 Buy target, Craig-Hallum holds an $18 Buy target, and Roth MKM's George Kelly cut his target to $9 from $13 with a Neutral rating.

The four targets average $16.25, rounded to $16 for readability, with an approximate range of $9 to $22. That wide spread captures a real divide: bullish analysts emphasize the company's turnaround and retail momentum, while the more cautious view focuses on shrinking revenue and a still-fragile growth story. Targets do not represent a guarantee, and the mean should not be read as an official published consensus figure.

Current Market Position and Path Toward the Target

At a recent close of $4.51, BODI carries a market capitalization of roughly $33 million. Reaching $16 would require an advance of approximately 255%, a very large move that would effectively undo most of the stock's steep decline over the past year. The company has shifted from its legacy multi-level marketing structure to an omni-channel, nutrition-led model, achieving positive net income and eleven consecutive quarters of positive adjusted EBITDA. Retail rollouts, including Shakeology at national vitamin retailers and new energy-drink lines, are early demand drivers, but revenue has still contracted sharply on a trailing-twelve-month basis, keeping the path toward $16 dependent on an unproven return to top-line growth.

What Could Support a Move Toward the Target

• Sustained profitability and disciplined cost control, with management reporting multiple quarters of positive adjusted EBITDA.
• Retail and Amazon channel expansion that broadens distribution beyond the legacy direct-selling base.
• Positioning in the wellness and weight-management market, which some analysts tie to rising GLP-1 treatment demand.
• An inexpensive-looking valuation on paper, with a trailing P/E (price-to-earnings ratio) near 2.7 and a price-to-sales ratio near 0.15.
• New product launches, including strength-training and energy-drink lines, that could widen the customer base.

What Could Prevent the Target From Being Reached

• A multi-year revenue decline that has not yet clearly reversed despite improved profitability.
• Micro-cap risk: a small float, low trading volume, and high volatility can amplify price swings in either direction.
• Recent analyst target cuts, including Roth MKM's reduction to $9, signaling skepticism about the pace of recovery.
• Competition in fitness streaming and nutrition from larger, better-capitalized rivals.
• A low Altman Z-score and modest working capital, which keep financial fragility a live concern.

Technical Levels and Market Structure

The 52-week range for BODI is roughly $4.01 to $16.87. The stock now sits near the lower end of that range, above the $4.01 support level, while the $16 target sits just beneath the prior $16.87 high. The 50-day moving average is near $4.78 and the 200-day moving average is near $8.96, meaning the shares trade below both and face meaningful overhead supply on any recovery. Round psychological levels near $5 and the 200-day average around $9 represent the first notable resistance zones on the way toward $16.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary and no formal timeline is guaranteed. The most important near-term events are quarterly earnings and guidance, with the next report scheduled for November 10, 2026. Investors should watch revenue trends and the nutrition mix, retail sell-through, any changes to analyst targets or ratings, gross-margin performance, and cash and debt levels, all of which could shift the market's view of whether a return toward the $16 objective is plausible.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For investors tracking a volatile small-cap name like BODI, combining AI-generated signals with fundamental research can add a useful layer of context.

Final Assessment

The $16 central target for The Beachbody Company represents the average of four verified analyst price targets, rounded from a $16.25 mean, and implies a roughly 255% advance from the recent $4.51 price. The bullish case rests on a genuine operational turnaround, sustained profitability, and retail expansion into the wellness market, while the bearish case points to ongoing revenue declines, analyst target cuts, and the fragility of a micro-cap with a wide $9-to-$22 target range. Reaching $16 would require not only maintaining profitability but proving a durable return to revenue growth. The question of whether BODI can reach that level remains an open, data-dependent one best assessed quarter by quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations